Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations

Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Current chemotherapy is quite toxic in growing children and more directed therapeutics are being sought. The IL-7R pathway is a major driver of ALL and here we evaluate two drugs directed to that pathway using a model of T cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Senkevitch, Emilee, Li, Wenqing, Hixon, Julie A., Andrews, Caroline, Cramer, Sarah D., Pauly, Gary T., Back, Timothy, Czarra, Kelli, Durum, Scott K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978251/
https://www.ncbi.nlm.nih.gov/pubmed/29854301
http://dx.doi.org/10.18632/oncotarget.25194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978251/
https://www.ncbi.nlm.nih.gov/pubmed/29854301
http://dx.doi.org/10.18632/oncotarget.25194

Ejemplares similares